English Deutsch 中文
  • Innovative Solutions
  • Expert Support and Knowledge
  • Reliable Cooperation
Menu Deutsch 中文

3SBio Licenses an Anti-VEGFR2/KDR mAb from PharmAbcine

Nov. 18, 2014

3SBio Inc., a leading China-based biotechnology company, announced on Nov. 18, 2014 that it has entered into an exclusive licensing agreement with Korea-based PharmAbcine, Inc. for the development, manufacturing and marketing of Tanibirumab, an anti-VEGFR2/KDR antibody for cancer, in the territory of Greater China and several emerging countries, including Thailand, Brazil and Russia. The deal included undisclosed upfront, milestone and royalty payments.